Ibuprofen/paracetamol - AFT Pharmaceuticals

Drug Profile

Ibuprofen/paracetamol - AFT Pharmaceuticals

Alternative Names: Acetaminophen/ibuprofen - AFT Pharmaceuticals; Acetaminophen/ibuprofen intravenous - AFT Pharmaceuticals; Acetaminophen/ibuprofen IV - AFT Pharmaceuticals; Maxigesic IV; Paracetamol/ibuprofen intravenous - AFT Pharmaceuticals

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AFT Pharmaceuticals
  • Class Anti-inflammatories; Non-opioid analgesics; Phenylpropionates
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Fever
  • Phase III Postoperative pain

Most Recent Events

  • 15 Sep 2017 AFT Pharmaceuticals completes a phase III trial in Postoperative pain in USA (IV) (NCT02689063)
  • 12 Jan 2017 Ibuprofen/parcetamol licensed to Weifa in Norway, Sweden, Denmark, Iceland and Finland for the treatment of Pain and Fever
  • 26 Oct 2016 Phase-III clinical trials in Postoperative pain in USA (IV) (NCT02689063)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top